Shattuck Labs (STTK) – Research Analysts’ Recent Ratings Changes

Shattuck Labs (NASDAQ: STTK) has recently received a number of price target changes and ratings updates:

• 10/11/2026 – Shattuck Labs is now covered by UBS Group. They set a “buy” rating and a $17.00 price target on the stock.
• 10/11/2026 – Shattuck Labs was upgraded by UBS Group to “strong-buy”.
• 10/2/2026 – Shattuck Labs had its price target raised by Wedbush from $11.00 to $14.00. They now have an “outperform” rating on the stock.
• 10/2/2026 – Shattuck Labs had its price target raised by Needham & Company LLC from $17.00 to $19.00. They now have a “buy” rating on the stock.
• 9/11/2026 – Shattuck Labs had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 8/24/2026 – Shattuck Labs is now covered by Raymond James Financial. They set a “strong-buy” rating and a $18.00 price target on the stock.
• 8/24/2026 – Shattuck Labs is now covered by Raymond James Financial. They set a “strong-buy” rating and a $18.00 price target on the stock.
• 8/24/2026 – Shattuck Labs was upgraded by TD Cowen to “strong-buy”.

Shattuck Labs, Inc is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The company’s research is based on its Agonist Redirected Checkpoint (ARC) platform, which is designed to combine immune-cell activation with checkpoint inhibition in a single therapeutic molecule.

Shattuck’s pipeline has included bifunctional fusion proteins such as SL-172154, an investigational therapy designed to engage CD40 ligand and block PD-L1, and SL-173154, which is designed to target CD27 ligand and PD-L1.